

1 **DISSECTING THE POLYHYDROXYALKANOATE-**  
2 **BINDING DOMAIN OF THE PhaF PHASIN: RATIONAL**  
3 **DESIGN OF A MINIMIZED AFFINITY TAG**

4 Running title: Rational design of a minimized PHA affinity tag

5 Aranzazu Mato<sup>a,b, †</sup>, Francisco G. Blanco<sup>a,b, †</sup>, Beatriz Maestro<sup>c</sup>, Jesús M. Sanz<sup>c,d</sup>, Jesús  
6 Pérez-Gil<sup>e</sup> and M. Auxiliadora Prieto<sup>a,b\*</sup>

7

8 <sup>a</sup>Polymer Biotechnology Group. Microbial and Plant Biotechnology Department, Centro  
9 de Investigaciones Biológicas Margarita Salas-CSIC, Madrid, Spain.

10 <sup>b</sup>Interdisciplinary Platform for Sustainable Plastics towards a Circular Economy-Spanish  
11 National Research Council (SusPlast-CSIC), Spain.

12 <sup>c</sup>Host-parasite Interplay In Pneumococcal Infection Group. Microbial and Plant  
13 Biotechnology Department, Centro de Investigaciones Biológicas Margarita Salas-CSIC,  
14 Madrid, Spain.

15 <sup>d</sup>Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES),  
16 Madrid, Spain

17 <sup>e</sup>Biochemical and Molecular Biology Department, Facultad de Ciencias Biológicas,  
18 Universidad Complutense de Madrid, Madrid, Spain.

19 <sup>†</sup>These authors contributed equally to this work. Order was decided by seniority.

20 \* Corresponding Author. <mailto:auxi@cib.csic.es>

21

## 22 **ABSTRACT**

23 Phasin PhaF from *Pseudomonas putida* consists of a modular protein whose N-terminal  
24 domain (BioF) has been demonstrated to be responsible for the binding to the PHA granule.  
25 BioF has been exploited with biotechnological purposes as an affinity tag in the  
26 functionalization of PHA beads with fusion proteins both *in vivo* and *in vitro*. The structural  
27 model of this domain suggests an amphipathic  $\alpha$ -helical conformation with the hydrophobic  
28 residues facing the PHA granule. In this work, we have analyzed the mean hydrophobicity  
29 and the hydrophobic moment of the native BioF tag to rationally design shorter versions  
30 that maintain the affinity for the granule. Hybrid proteins containing the green fluorescent  
31 protein (GFP) fused to the BioF derivatives were studied for *in vivo* localization on the  
32 PHA, stability on the surface of the PHA granule against pH, temperature and ionic strength,  
33 and their possible influence on the PHA synthesis. Based on the results obtained, a minimized  
34 BioF tag for PHA functionalization has been proposed (MinP), which retains similar  
35 binding properties but possesses an attractive biotechnological potential derived from its  
36 reduced size. The MinP tag was further validated by analyzing functionality and stability of  
37 the fusion proteins MinP- $\beta$ -galactosidase and MinP-CueO from *Escherichia coli*.

## 38 **IMPORTANCE**

39 Polyhydroxyalkanoates (PHAs) are biocompatible, non-toxic and biodegradable  
40 biopolymers with exceptional applications in the industrial and medical fields. The complex  
41 structure of the PHA granule can be exploited as a toolbox to display molecules of interest  
42 on their surface. Phasins, the most abundant group of proteins on the granule, have been  
43 employed as anchoring tags to obtain functionalized PHA beads for high-affinity  
44 bioseparation, enzyme immobilization, diagnostics or cell targeting. Here, a shorter module

45 based on the previously designed BioF tag has been demonstrated to maintain the affinity for  
46 the PHA granule, with higher stability and similar functionalization efficiency. The use of  
47 a 67 % shorter peptide, which maintains the binding properties of the entire protein,  
48 constitutes an advantage for the immobilization of recombinant proteins on the PHA surface  
49 both *in vitro* and *in vivo*.

50       **INTRODUCTION**

51       Display of functional proteins on solid supports constitutes an important tool for many  
52       industrial and biomedical purposes (1). In this vein, nanoparticles functionalized with  
53       peptides and proteins may be widely employed for therapeutic applications, acting as  
54       drug carriers, anti-tumor and bactericidal drugs or cellular targeting moieties (2).  
55       Strategies for protein immobilization vary depending on the matrixes employed and the  
56       final application, and they may include non-specific adsorption, chemical cross-linking  
57       or the use of affinity tags (3).

58       The biodegradable and biocompatible polyhydroxyalkanoates (PHA) are bacterial  
59       storage polyesters which are gaining much attention as highly-tunable materials for the  
60       development of a variety of biomedical and industrial devices. This is mainly due to  
61       the structural versatility that can be obtained by bacterial fermentation and post-  
62       biosynthetic modifications (4). These polymers are synthesized as hydrophobic inclusions  
63       surrounded by a layer of proteins involved in the PHA metabolism, called granule  
64       associated proteins (GAPs). Among them, the most remarkable are PHA polymerases  
65       and depolymerases, as well as phasins, which are amphipathic proteins coating the PHA  
66       granule (Fig. 1) (5). The complex architecture of PHA granules offers a toolbox to  
67       display molecules of interest on their surface (6). GAPs have been used as anchoring tags  
68       to immobilize value-added proteins on the surface of PHA materials. Depending on the  
69       target application, functionalization by using GAP-fusion proteins may be achieved *in*  
70       *vivo* (simultaneously to the PHA production in the bacterial cytoplasm) or *in vitro*  
71       (utilizing endotoxin free PHA purified after the biotechnological production) (7).  
72       The first strategy led to GAP-fusion proteins immobilized onto the PHA surface

73 simultaneously with their synthesis. The second approach requires the extraction of the  
74 polyester, its conversion into nanoparticles or films, and the subsequent *in vitro*  
75 immobilization of the GAP-fusion. This strategy is convenient for biomedical purposes  
76 that require endotoxin-free PHA materials and a control of the amount of the immobilized  
77 protein. Among GAPs, phasins constitute the most abundant group of proteins covering  
78 the granule (8, 9) and have been widely used as anchoring tags to functionalize PHA  
79 supports for a variety of applications such as affinity bio-separation (10), protein  
80 purification (11-13), enzyme immobilization (14-16), protein delivery to natural  
81 environments (17), diagnostics (18, 19), cell targeting (20-24) and antimicrobials (25).

82 PhaF from *Pseudomonas putida* is a prototypic and well characterized phasin (26, 27).  
83 It is a partially intrinsically disordered protein consisting of two domains connected by a  
84 leucine zipper motif that is responsible for its oligomerization (28, 29). The 142-aa  
85 BioF module, containing the N-terminal and the leucine zipper sequences, has been  
86 extensively demonstrated to bind to PHA granules (17, 30, 31). Even more, the BioF  
87 domain binds not only to PHA materials *in vitro* but also to other hydrophobic-  
88 hydrophilic interfaces such as those containing phospholipids, making it a versatile tag  
89 to combine with a variety of hydrophobic supports (14, 32). One of the drawbacks of  
90 applying the BioF tag for biomedical applications is its size, as a smaller peptide would  
91 be more desirable to reduce potential interferences with correct folding and activity of  
92 the tagged protein of interest (33).

93 Based on the predicted structural model of PhaF that supports a conformation-dependent  
94 binding of the BioF fragment to the PHA granule (28), we have explored the ability of  
95 reduced segments of BioF to maintain the capacity to bind PHA, with the aim of finding

96 a shorter, yet fully functional, BioF segment to be used as an efficient affinity tag for  
97 recombinant protein immobilization.

98     **RESULTS**

99     ***BioF-based-tag design based on structure prediction***

100     The N-terminal domain of the PhaF (N-PhaF) is predicted to form a long, largely amphipathic  
101      $\alpha$ -helix that interacts with PHA through hydrophobic interactions while exposing the  
102     hydrophilic side to solvent or cytoplasmic fraction of the cell (27). A *HeliQuest* analysis of the  
103     N-PhaF sequence shows the mean hydrophobicity ( $\langle H \rangle$ ) and the amphipaticity (*i.e.*,  
104     hydrophobic moment,  $\langle \mu H \rangle$ ) of all possible 18-aa  $\alpha$ -helical stretches within this domain  
105     (Fig. 2A) and reveals fluctuations of both properties throughout the domain. Interestingly,  
106     the region consisting of residues 33-49 simultaneously exhibits relatively high values of both  
107      $\langle H \rangle$  and  $\langle \mu H \rangle$ , while residues 58-91 displayed the lowest values of  $\langle H \rangle$  and  $\langle \mu H \rangle$ . This latter  
108     region has been suggested to be natively unfolded in solution when not complexed with PHA  
109     (28) (Fig. 2A). To further determine the contributions of different segments of N-PhaF to the  
110     binding to PHA, we designed shortened versions of BioF (Fig. 2B), differing in polarity,  
111     amphipaticity and length, namely Bi1, Bi2, Bi3 and Bi4. The Bi1 segment contains the N-  
112     terminal region and the most hydrophobic stretches, including the 26-32 subsequence  
113     (WLAGLGI) that is conserved in all PhaF-like phasin proteins and has been proposed to  
114     play a fundamental role in the interaction of phasins with PHA granules (30). Bi2 contains the  
115     33-49 subsequence mentioned above, whereas Bi3 starts with the Bi2 segment and extends  
116     to contain the central leucine zipper region. Finally, the Bi4 segment was designed on a different  
117     basis, as it only contains the predicted leucine zipper motif involved in PhaF  
118     oligomerization along with a short adjacent sequence (28, 29).

119     ***In vivo localization of BioF-based fragments in P. putida KT2440***

120 To study the *in vivo* PHA binding properties of the different Bi segments, we designed  
121 several green fluorescent protein (GFP) fusion constructs, which allowed for the determination  
122 of their intracellular localization. Each construct (named Bi1-G, Bi2-G, Bi3-G, Bi4-G and  
123 BioF-G) was inserted in the pSEVA238 plasmid under the control of the XylS/*Pm*  
124 regulator/promoter system (Table 3) (35) and introduced into *P. putida* KT2440. Cultures  
125 were grown in 0.1 N M63 plus 15 mM of octanoate to favour PHA accumulation, and the  
126 production of the corresponding recombinant protein was induced at O.D.<sub>600</sub> 0.8 by the addition  
127 of 1 mM of 3-methylbenzoate (3-MB). After 24 h of growth, cells were observed through  
128 epifluorescence microscopy (Fig. 3A). A common phenotype was detected in the strains  
129 containing BioF-G, Bi1-G, Bi3-G, and Bi4-G fusions, which showed an enriched ring of  
130 fluorescence surrounding the PHA granules (Fig. 3A). This pattern suggests the localization  
131 of these fusion proteins on the surface of the granules. A different phenotype could be observed  
132 in cells containing the shortest segment Bi2-G, in which the protein was observed to be  
133 homogeneously distributed throughout the cytoplasm. This localization technique was  
134 complemented by glycerol gradient separation and isolation of PHA granules from cells  
135 producing the Bi-G segments (see Materials and Methods section for details). Supernatant and  
136 pellet fractions of crude extracts and purified granules were separated by SDS-PAGE (Fig.  
137 3B). Bi1-G, Bi3-G and BioF-G proteins were detected in the granule fraction while Bi2-G was  
138 only detected in the supernatant of the crude extract, validating the results obtained  
139 microscopically. Some Bi3-G and BioF-G proteins were also detected in the supernatant fraction  
140 of the crude extract. The inability to detect Bi4-G in any fraction by SDS-PAGE suggests either  
141 that this polypeptide is produced at a low level, it is unstable, or forms aggregates that cannot  
142 enter the gel. Due to these possibilities the Bi4 segment was discarded for further studies.

143 *In vivo localization of BioF-based fragments in a P. putida KT2440  $\Delta$ pha strain containing*  
144 *PhaC1 synthase*

145 Phasins covering the PHA granule have been demonstrated to interact with other granule  
146 associated proteins (GAPs) through the leucine zipper motif (29). In order to avoid potential  
147 interference by the presence of other GAPs on the surface of the PHA granule, a *P. putida*  
148 KT2440 mutant lacking the *pha* gene cluster was employed as a host to introduce solely the  
149 *phaC1* synthase gene, sufficient to produce a low level of PHA. The *phaC1* expression was  
150 under the control of a weak constitutive promoter and integrated in the chromosome via the  
151 pTn7-M transposon system. The resulting strain was named  $\Delta$ pha+C1 and employed to confirm  
152 the ability of the Bi fragments to maintain their affinity for the PHA granule in the absence of  
153 other phasins and GAP proteins.

154 The plasmids coding the different Bi segment-GFP fusion constructs were introduced into the  
155  $\Delta$ pha+C1 strain and assessed for localization by epifluorescence microscopy. The Bi1-G  
156 protein was observed to localize in rings surrounding the PHA granules as the control BioF-  
157 G protein (Fig. 4A), and both proteins were detected in the pellet and PHA granule fractions,  
158 with additional presence of BioF-G in the supernatant portion (Fig. 4B). Bi3-G showed a  
159 similar localization pattern as BioF-G, with some fluorescence observed in the cytoplasm out  
160 from the granule surface (Fig. 4A). These results are in agreement with the fractionation  
161 studies (Fig. 4B), as some Bi3-G and BioF-G were detected in the soluble fraction. Besides,  
162 some degradation of Bi3-G seemed to occur indicated as double red arrows in Fig. 4B. In  
163 the case of Bi2-G, the fluorescence was found distributed inside the whole cell suggesting again  
164 that this segment is unable to bind to PHA granules (Fig. 4A). This hypothesis is further

165 confirmed by the lack of granule association in the fractionation experiment (Fig. 4B).

### 166 ***Stability of BioF-based structures on the PHA granule***

167 Previous work had demonstrated the stability of adsorption of BioF fusion proteins to isolated  
168 PHA granules through the application of a panel of detergents (14, 30). One of the most effective  
169 detergents for disrupting the BioF-PHA granule interaction is Triton X-100. Thus, we used this  
170 detergent to assess the binding strength of the three efficient adsorption variants to PHA, Bi1-  
171 G, Bi3-G and BioF-G. PHA granules isolated from a 50 mL culture of *P. putida* KT2440  
172  $\Delta pha+C1$  strains were resuspended in different concentrations of Triton X-100 and incubated 2  
173 h at room temperature. After the treatment, the supernatant and pellet fractions of the suspension  
174 were separated, and the protein released from the granules was evaluated by SDS-PAGE (Fig.  
175 S1).

176 The gel band intensities were used to calculate the percentage of Bi segment protein released  
177 from the PHA granules (Fig. 5). The data indicates that Bi3-G presents the weakest interaction  
178 with the PHA granules, even in the absence of detergent. In contrast, the protein Bi1-G was not  
179 released in the absence of detergent and, in any case, it remained adsorbed in ca. 90 % on the  
180 granule even at 1.5 % of Triton X-100, surpassing the native BioF-G. This indicates that Bi1  
181 displays an affinity to PHA granules similar or even higher than BioF and therefore we  
182 focused our efforts to further evaluate this segment as a potential tag for biotechnological uses.

183 Next, the stability of the binding between Bi1-G and PHA granules under different  
184 physicochemical conditions (temperature, ionic strength and pH) was evaluated. An aliquot of  
185 PHA granules containing Bi1-G was resuspended in buffer containing the specified condition

186 and incubated for 2 h at the indicated temperature, or otherwise 4 °C, and followed by separation  
187 of the supernatant and pellet fractions. As can be observed in Fig. 6, the protein mostly remained  
188 attached to the granule at the different temperatures (-20 °C, 4°C, 37 °C and 60 °C), ionic  
189 strengths (10 mM, 100 mM and 1 M NaCl) and pH's (pH 3.0, pH 5.0, pH 7.0 and pH 9.0)  
190 tested, although some degradation occurred upon incubation at pH 3.0.

### 191 ***Influence of fusion proteins on PHA production and functionalization efficiency***

192 The Bi1 segment was considered a promising choice as an optimized PHA affinity tag due to  
193 the short size of the fragment, co-localization with PHA granules *in vivo* and its persistent  
194 interaction with PHA *ex vivo* under different physicochemical conditions, comparable to the  
195 BioF-PHA interaction. With the aim of studying the potential of Bi1 to be used as an affinity  
196 tag, the effect of the production of this protein on PHA production and PHA granule  
197 functionalization was evaluated. Strains producing BioF-G and Bi1-G, or harbouring an empty  
198 vector as a control, were analysed for PHA production (Table 1). The presence of any plasmid  
199 whether empty vector or BioF-G or Bi1-G encoding genes resulted in a roughly 20 % decrease  
200 in PHA production in recombinant strains. Interestingly, in the  $\Delta pha+CI$  background the  
201 presence of the whole BioF increased the percentage of PHA when compared to Bi1-G producing  
202 or empty vector cells, 38 % versus ~27 %, respectively. Conversely, this effect was not  
203 maintained in the wild type strain, where the PHA accumulation was similar among all the  
204 strains containing plasmid. The concentration of granule-associated proteins was also measured  
205 by quantifying bands from SDS-PAGE isolated PHA granules. In the  $\Delta pha+CI$  background, a  
206 higher amount of granule-associated BioF-G (8 mg per gram of PHA) was observed compared  
207 to Bi1-G (5.8 mg per gram of PHA). However, in molar terms, little difference was detected

208 between the two segments, with the presence of protein at 0.17  $\mu\text{M}$  and 0.16  $\mu\text{M}$  per gram of  
209 PHA for BioF-G and Bi1-G, respectively.

### 210 ***Construction of a plasmid based on Bi1 for PHA functionalization***

211 The Bi1 fragment demonstrated an interaction with PHA granules with superior  
212 functionalization efficiency and a strong stability making this construct suitable to be used as  
213 a tag to display functional proteins on the surface of PHA materials. Based on this  
214 optimized tag, hereafter named MinP, a fusion plasmid based on pSEVA238 was designed to  
215 simplify the production of protein-functionalized PHA nanobeads. The MinP fusion plasmid  
216 allows for induced expression under the control of *xyIS/P<sub>m</sub>* system and was modified to  
217 incorporate a RBS followed by the MinP tag in order to allow N-terminal fusions of the  
218 protein of interest (Fig. 7A). The novel plasmid, called pSMinPN, contains a multicloning site  
219 (MCS) separated from the *minP* sequence by a glycine-rich linker region (*Linker*) which can  
220 be removed if desired by using two engineered flanking *XhoI* sites. This linker can also be  
221 replaced by other spacer regions or to include an intein site, expanding its potential applications.  
222 As a proof of concept, a *minP-GFP* fusion gene was constructed in pSMinPN, transformed  
223 into  *$\Delta\text{pha}+CI$* , and co-localization of MinP-GFP with PHA granules was observed by  
224 fluorescence microscopy following induction (Fig. 7B).

### 225 ***Validation of the MinP tag for enzymes immobilization***

226 To validate the MinP as affinity tag, two enzymes, the  $\beta$ -galactosidase and the CueO oxidase  
227 from *E. coli* were genetically fused to *minP* by using the designed plasmid pSMinPN. Both  
228 enzymes are of wide applicability in the food industry for manufacturing lactose-hydrolyzed

229 products and production of galactosylated products, in the case of the  $\beta$ -galactosidase (36), and  
230 for the textile and paper industries as well as for organic compounds degradation with CueO  
231 oxidase (15, 37). The  $\beta$ -galactosidase coding gene was introduced by conventional cloning into  
232 *XhoI* and *BamHI* sites, resulting in pSMinP-2 plasmid, and the *cueO* gene into *XhoI* and *HindIII*  
233 sites resulting in the plasmid pSMinP-3. Both were independently transferred to *P. putida*  
234 KT2440  $\Delta pha+C1$  and both strains, KT2440  $\Delta pha+C1$  (pSMinP-2) and *P. putida* KT2440  
235  $\Delta pha+C1$  (pSMinP-3) were able to produce the fusion proteins of 122 kDa and 59 kDa  
236 respectively (Fig S2). The fusion proteins were able to bind to the PHA granules, and the binding  
237 stability under different physicochemical conditions (temperature, ionic strength and pH) was  
238 evaluated as described above. As can be observed in Table 2, the fusion proteins remained  
239 attached to the granules at percentages  $\geq 85$  % in all conditions for both MinP- $\beta$ -galactosidase  
240 and MinP-CueO (Table 2), confirming the suitability of the MinP system for immobilizing  
241 recombinant proteins into PHA granules. Maximal release was observed for MinP-CueO at pH  
242 9.0 (17 %) and for MinP- $\beta$ -galactosidase at 37 °C (24 %) The latter was degraded after the  
243 treatment at 60 °C.

244 Additionally, the release of the fusion proteins was tested in the presence of different  
245 percentages of Triton X-100 (Fig. S3). A similar pattern than that observed for Bi1-G was  
246 obtained for the MinP- $\beta$ -galactosidase, where 0.15 % (v/v) of detergent treatment yielded higher  
247 release of protein from the granules than the assay carried out at 1.5 % (v/v) of Triton X-100.  
248 However, in the case of MinP-CueO, both detergent percentages resulted in similar protein  
249 release. These results suggest that the release of MinP-fusions is not proportional to the detergent  
250 concentration and, together with those depicted in Fig. 5, indicate that the elution yields strongly

251 depend on the fused polypeptide and do not follow a simple trend with detergent concentration.  
252 This behaviour variety has also been found with the interaction of different BioF fusions with  
253 polyhydroxybutyrate granules (14) and suggests that detergent elution is a complex  
254 phenomenon involving both the affinity tag and the fused moiety that deserves a further  
255 molecular investigation.

256 To further validate the MinP tag system, the activity of each fusion enzyme was measured after  
257 treatment at different pHs (3.0, 5.0, 7.0 and 9.0) and temperatures (-20 °C, 4 °C, 37°C and 60  
258 °C). As it can be observed in Fig. 8, immobilized MinP-β-galactosidase preserves the enzyme  
259 activity excepting at pH 3.0 (Fig. 8A) and 60 °C (Fig. 8B). Similar results were obtained with  
260 immobilized MinP-CueO (Fig. 8C-D), suggesting that either the proteins, the polymer support  
261 or both, are affected under these extreme conditions.

262 Finally, the functionalization ratio was calculated as explained above for both enzymes. The  
263 ratios of mg of protein per gram of PHA were of  $16.8 \pm 1.6$  for MinP-β-galactosidase and  $8.5 \pm$   
264  $0.4$  for MinP-CueO. However, when calculated in molar terms, both proteins had similar  
265 functionalization ratios of  $0.14 \pm 0.03$  μM per gram of PHA for MinP-β-galactosidase and  $0.14$   
266  $\pm 0.06$  μM per gram of PHA for MinP-CueO, consistent with the results for MinP-GFP ( $0.16$   
267 μM per gram of PHA).

268     **DISCUSSION**

269     This work addressed two main goals: to gain a better understanding on the binding capacity of  
270     BioF to the PHA granule and to use this knowledge to obtain improved versions of the tag  
271     that expands its biotechnological potential.

272     Many GAPs have been exploited as tags for the functionalization of PHA, especially PHA  
273     synthases and phasins. The mechanisms of the binding of these tags to the PHA material and  
274     the strength of the interaction are different, as well as the properties of each tag, making  
275     them suitable depending on the target application. Phasins constitute an attractive tool for  
276     tuning PHA materials due to their strong affinity to PHA. Despite that only a few studies have  
277     addressed the structural aspects of phasins, it is known that some common characteristics  
278     include the high proportion of disordered regions (28, 38), the presence of residues in  $\alpha$ -  
279     helical conformation that increases in the presence of PHA (9, 28), and their tendency to  
280     form oligomers in solution (8, 28, 29, 39).

281     The PhaF phasin from *P. putida*, constitutes an attractive biotechnology tool, as its N-terminal  
282     domain (the BioF affinity tag) binds to PHA granules by non-specific hydrophobic interactions.  
283     In this work, various polypeptides based on BioF have been designed, differing in polarity,  
284     amphipaticity and length: Bi1, Bi2, Bi3 and Bi4 (Fig. 2). All of them, except Bi2, were able to  
285     bind *in vivo* to PHA granules, suggesting that substrate recognition does not reside in a specific  
286     region (Fig. 3). Bi2 was unable to bind to the granule, likely due to its short size preventing the  
287     establishment of sufficient hydrophobic interactions with the polymer. The binding of the BioF-  
288     based peptides to PHA granules was demonstrated to be independent of the presence of other  
289     GAPs such as phasins and depolymerase on the surface of the granule (Fig. 4). The presence

290 of PhaC1 and FadD could not be avoided due to their essential function for PHA accumulation,  
291 but our results indicate that the presence of most of the GAPs is dispensable for BioF  
292 segment binding.

293 The affinity of the truncated forms of the BioF tag to PHA was tested using various approaches.  
294 The Bi3 displays a similar PHA localization pattern than BioF (Fig. 3B) although with a lower  
295 binding strength (Fig. 5). On the other hand, and although localized predominantly on the PHA  
296 granule surface by microscopy (Fig. 3A), the Bi4 segment did not show effective binding to  
297 isolated PHA granules (Fig. 3B). Previous studies have demonstrated that the inclusion of a  
298 functional leucine zipper motif is important for the oligomerization of PhaF (8, 28, 29).  
299 However, as both Bi3 and Bi4 share the same leucine zipper region, these effects put into  
300 question the crucial relevance of this motif for PHA affinity. Regarding the Bi1 fragment,  
301 containing the BioF N-terminal region, it exhibited a PHA binding affinity similar to that of  
302 whole BioF, whereas Bi3, containing the C-terminal region of BioF, displayed a reduced  
303 binding strength, despite both peptides sharing a common region that corresponds to the Bi2  
304 segment. This divergence could be attributed to the different hydrophobic and amphipathic  
305 characteristics of both polypeptides (Fig. 1), rather than solely being a function of their  
306 lengths. In fact, mean hydrophobicity seems to be a dominant factor for PHA binding more so  
307 than amphipathicity, as the Bi1 fragment displays a clear higher value of  $\langle H \rangle$  than Bi3, while it  
308 presents only a moderate value for the hydrophobic moment  $\langle \mu H \rangle$  (Fig. 2A). Moreover, Bi3 also  
309 contains a region that is presumably natively unfolded in solution that may result in an increased  
310 propensity for proteolytic attack (28). The two Bi3 bands observed in Fig. 3B may be due to this  
311 feature.

312 The 48 amino acid segment Bi1 was chosen as an optimized tag for PHA functionalization and  
313 was renamed MinP. Its binding capacity under different physicochemical conditions were  
314 comparable or even stronger than full-length BioF (Fig. 3 - 5 and 6, 14, 29). The stability of  
315 the binding between the tag and PHA is important to apply these devices across a variety  
316 of physicochemical conditions, as many industrial processes take place at extreme temperatures  
317 or pH (40, 41), conditions in which we demonstrate that MinP is retained at the surface of  
318 the PHA granule (Fig. 5 and 6, table 2). The high stability of MinP on the surface of the PHA  
319 granule constitutes a good choice for a strong immobilization of proteins and complements the  
320 diversity of PHA affinity tags tailored to any need.

321 The amount of fusion protein attached to PHA granules was observed to be similar for BioF and  
322 MinP, both in wild-type and  $\Delta pha+Cl$  strains (Table 1). Likewise, similar functionalization  
323 in molar terms was obtained for MinP-CueO and MinP- $\beta$ -galactosidase fusions. This suggests  
324 that the PHA-binding capability of BioF mainly resides in its N-terminal moiety, and that the  
325 presence of other GAPs on the surface of the granule does not impact in the functionalization  
326 efficiency when the levels of the recombinant protein inside the cell are much higher than other  
327 GAPs, as was previously observed (30).

328 Phasins have a positive effect on PHA production and PHA granule biogenesis (27, 31).  
329 This has been proposed to be related with the interfacial role of phasins to segregate the  
330 hydrophobic PHA granules away from hydrophilic cytoplasm, avoiding potential deleterious  
331 effects of PHA production (42, 43). We observed the positive effects of the production  
332 of phasin segments in Table 1, where presence of BioF increased the amount of PHA produced  
333 in the  $\Delta pha+Cl$  strain, while MinP production did not. BioF tag presence likely favours

334 granule formation and thus improves the PHA production, whereas MinP appears to not  
335 have complete phasin activity. This could be due to the lack of the leucine zipper motif in  
336 MinP, which is important for oligomerization and to establish the layer of GAPs that cover  
337 the PHA granule (29). Concerning the segregation of PHA granules, driven by the natural PhaF  
338 (27), it is affected in the absence of this protein, very likely influencing the PHA accumulation.  
339 This decrease in production could be solved by introducing the natural phasin PhaF if an  
340 industrial exploitation of the system that requires maximization of the PHA yield would be  
341 envisaged.

342 Finally, we propose a construction based on plasmid pSEVA238 to implement the production  
343 of fusion proteins at the C-terminal domain of MinP tag, and containing a movable  
344 linker as well as a MCS for cloning. The SEVA plasmids constitute a versatile platform for  
345 swapping modules as required (<http://seva.cnb.csic.es/>). The MinP module can be thus  
346 incorporated into the standardized synthetic biology library as a novel brick for polyester  
347 functionalization.

348 **MATERIALS AND METHODS**

349 ***Strains, media and growth conditions***

350 The bacterial strains used in this study are listed in Table 3. *E. coli* and *P. putida* strains  
351 were grown routinely in Lysogeny Broth (LB) medium (44) at 37 °C and 30 °C, respectively,  
352 in a horizontal shaker at 200 rpm. Solid media were supplemented with 1.5 % (w/v) agar.  
353 Kanamycin antibiotic was added when needed at final concentration of 50 µg/mL.

354 For PHA production, the experiments were performed in 0.1 N M63 (13.6 g KH<sub>2</sub>PO<sub>4</sub>, 0.2 g  
355 (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.5 mg FeSO<sub>4</sub>·7 H<sub>2</sub>O to 1 L, adjusted to pH 7.0 with KOH) containing 15 mM  
356 sodium octanoate. This is a nitrogen limited medium for PHA production, where 0.1 N means a  
357 10 % of the nitrogen source concentration of the standard M63 medium (2 g L<sup>-1</sup>). A 20 mL  
358 overnight culture grown in LB at 30 °C and 200 rpm was washed with 10 mL 145 mM NaCl,  
359 inoculated at OD<sub>600</sub> 0.3 in 100 mL 0.1 N M63 medium and grown at 30 °C, as previously  
360 described (30). Minimal medium was supplemented with 1 mM MgSO<sub>4</sub> and a 0.1 mL of a  
361 solution of trace elements (for 1 L: 2.78 g FeSO<sub>4</sub>·7H<sub>2</sub>O, 1.98 g MnCl<sub>2</sub>·4H<sub>2</sub>O, 2.81 g  
362 CoSO<sub>4</sub>·7H<sub>2</sub>O, 1.47 g CaCl<sub>2</sub>·2H<sub>2</sub>O, 0.17 g CuCl<sub>2</sub>·2H<sub>2</sub>O, 0.29 g ZnSO<sub>4</sub>·7H<sub>2</sub>O in 1 N HCl). When  
363 necessary, 3-methylbenzoate (3MB) was added in a final concentration of 1 mM for induction  
364 of pSEVA238 derivative plasmids (35).

365 ***DNA manipulation, plasmid and strain constructions***

366 DNA manipulations were performed as previously described (44) and the whole  
367 oligonucleotides used are listed in Table 3.

368 For the construction of the strain carrying the PhaC1 polymerase, a modifiable cluster  
369 was *in silico* designed (Fig. 9). The synthesis was carried out by the GenBank® company.  
370 The cluster allows the introduction of other modules through Gibson Assembly technique  
371 (53) by using the overlap neutral regions (named as “1, 2”). Besides, promoters and cargo  
372 gene can be easily exchanged using *XbaI/XhoI/BamHI* restriction sites. The cluster is  
373 flanked by two *NotI* sites to be cloned into pTn7-M transposon for integration in *P.*  
374 *putida* KT2440  $\Delta$ *pha* genome. The *phaC1* gene was introduced under the control of a  
375 constitutive synthetic promoter (*P*<sub>14a</sub> promoter) (49), and the corresponding strain was  
376 called *P. putida* KT2440  $\Delta$ *pha*+C1. The *M1-PhaC1-T0* module was synthesized  
377 modifying the nucleotide sequence (Fig. S4) to avoid the restriction sites specified in Fig.  
378 9 and introduced in the pTn7-M plasmid for integration in *P. putida* KT2440  $\Delta$ *pha* genome  
379 (Table 3).

380 For the construction of the pSMinPN plasmid, the sequence containing the *minP* gene  
381 followed by a linker and flanked by *XhoI* restriction sites and a multiple cloning site (MCS)  
382 was designed and synthesized. The construct was amplified using primers minPNt-F and  
383 minPNt-R (Table 3) and cloned into pSEVA238 by using the *EcoRI* and *HindIII* restriction  
384 enzymes. The gene coding for green fluorescent protein (GFP) was cloned into the pSMinPN  
385 plasmid between the *XhoI* and *HindIII* sites to generate pSMinP-1 and transformed by  
386 electroporation into *P. putida* KT2440  $\Delta$ *pha*+C1 (Table 3). For the construction of the  
387 pSMinP-2 and pSMinP-3 plasmids, the genes coding for the  $\beta$ -galactosidase (*lacZ*) and

388 CueO (*cueO*) were amplified from pSEVA225 and pCueO respectively (Table 3), using  
389 the XhoI-LacZ-F and BamHI-LacZ-R oligonucleotides for *lacZ* and XhoI-CueO-F and  
390 HindIII-CueO-R for *cueO* (Table 3). Each one was cloned onto the 3' end of the MinP tag  
391 of pSMinPN plasmid between the *XhoI*/*BamHI* and *XhoI*/*HindIII* sites for *lacZ* and *cueO*  
392 respectively. Plasmids pSMinP-2 and pSMinP-3 were independently transferred by  
393 electroporation to *P. putida* KT2440  $\Delta pha+C1$ .

#### 394 ***Protein structure prediction***

395 All predicted  $\alpha$ -helical sequences (18-aa windows) were analyzed for their  
396 hydrophobicity and amphipathicity with the *HeliQuest* utilities  
397 (<http://heliquet.ipmc.cnrs.fr/>) (34) using the Fauchere and Pliska scale (54) to  
398 calculate the mean hydrophobicity ( $\langle H \rangle$ ), while the mean hydrophobic moment ( $\langle \mu H \rangle$ )  
399 was calculated according to Eisenberg *et al.* (55). The hydrophobic moment is a  
400 measure of the amphipathicity of a helix where each amino acid is assigned a value  
401 (positive or negative) according to its hydrophobicity. Mean hydrophobicity is the sum  
402 of the hydrophobicity values divided by the number of residues (GenScript, s.f.).

#### 403 ***BioF library construction***

404 Based on structure prediction and hydropathic profile of BioF, several potential PHA  
405 affinity tags were constructed (Fig. 2). Different PCR products were obtained using  
406 the oligonucleotides Bio1-F and Bio1-R (Bi1); Bio1-F and Bio4-R (BioF); Bio2-F and  
407 Bio1-R (Bi2); Bio3-F and Bio3-R (Bi4); Bio2-F and Bio3-R (Bi3) with *P. putida* KT2440  
408 genomic DNA as template (Table 3). The corresponding DNA fragments were cloned into  
409 pSP1 plasmid (Table 3) using *NdeI* and *HindIII* restriction enzymes, giving the plasmids:

410 pSP1Bi1, pSP1Bi2, pSP1Bi3, pSP1Bi4 and pSP1BioF (Table 2). To allow the *in vivo*  
411 localization of each BioF-derived polypeptide, the gene coding for the GFP was  
412 amplified from pMAB20-GFP-LYTAG plasmid (31) by using the GFP-F and GFP-R  
413 oligonucleotides (Table 3) and cloned onto the 3' end of the Bi-G segments between the  
414 *XhoI* and *HindIII* restriction sites. The plasmids were finally transformed by  
415 electroporation into *P. putida* KT2440. The most promising designs were also  
416 introduced into *P. putida* KT2440  $\Delta$ *pha*+C1.

#### 417 ***Fluorescence microscopy***

418 Strains *P. putida* KT2440 and *P. putida* KT2440  $\Delta$ *pha*+C1 carrying the corresponding  
419 plasmid: pSP1Bi1-G, pSP1Bi2-G, pSP1Bi3-G, pSP1Bi4-G or pSP1BioF-G (Table 3)  
420 were grown in PHA producing media for 24 h at 30 °C and 200 rpm. The induction  
421 of the corresponding genes was carried out at OD<sub>600</sub> 0.8 by the addition of 1 mM 3MB.  
422 After 20 h of induction, the cells were directly observed through a Wide Field  
423 Multidimensional Microscopy System Leica AF6000 LX, equipped with a CCD  
424 Hamamatsu C9100-02 digital camera. Live cell imaging was performed using an 100x/AN  
425 1.4 oil immersion, and GFP fluorescence was collected using a GFP-3035C-000 Semrock  
426 filter, with excitation and emission ranges of 472/30 nm and 520/35 nm respectively, and  
427 a 495 nm dichroic mirror.

#### 428 ***PHA Granules isolation***

429 The PHA granules from *P. putida* KT2440 and *P. putida* KT2440  $\Delta$ *pha*+C1 strains  
430 carrying the corresponding plasmid: pSP1Bi1-G, pSP1Bi2-G, pSP1Bi3-G or pSP1BioF-  
431 G were isolated following the protocol previously described (31). Briefly, bacterial cells

432 from a 14 mL of an OD<sub>600</sub> 2-3 culture (except otherwise specified) were harvested by  
433 centrifugation at 12,000 x g for 20 min, suspended in 7 mL of 15 mM Tris HCl pH 8.0,  
434 and disrupted twice by French Press (1,000 psi). The resulting suspension was  
435 centrifuged 30 min at 12,000 x g, and the pellet fraction was resuspended in 5 mL of 15  
436 mM Tris HCl pH 8.0 and layered over 5 mL of 55 % glycerol. The solution was  
437 centrifuged at 17,000 x g for 30 min, and the isolated granules were washed twice with  
438 15 mM Tris HCl pH 8.0 to remove the residual glycerol, and suspended into 0.5-1.5 mL  
439 of 15 mM Tris HCl pH 8.0.

#### 440 ***Stability of MinP-proteins attached to the PHA granule***

441 An aliquot of 100 µL of the isolated granules from KT2440  $\Delta pha+Cl$  (see *PHA*  
442 *granules isolation*) containing the plasmid coding for the corresponding BioF-derived  
443 polypeptide were collected by centrifugation, suspended in Triton X-100 at different  
444 concentrations (0.015 %, 0.15 %, 1.5 % in 15 mM Tris HCl pH 8.0, v/v) and incubated  
445 for 2 h at room temperature. The assay was later repeated with the final fusion proteins  
446 MinP-CueO and MinP- $\beta$ -galactosidase.

447 The binding stability of Bi1-G protein, MinP-CueO and MinP- $\beta$ -galactosidase to the PHA  
448 granules was also tested under different temperature, pH and ionic strength conditions as  
449 previously described (29). Briefly, an aliquot of 100 µL of purified granules from *P.*  
450 *putida* KT2440  $\Delta pha+Cl$  (pSP1Bi1-G, pSPMinP-2 and pSPMinP-3) (see *PHA granules*  
451 *isolation*) was incubated for 2 h (i) in 100 µL of 15 mM Tris HCl pH 8.0 at different  
452 temperatures: -20, 4, 37 or 60 °C; (ii) in 100 µL of 0, 10, 100, 1000 mM NaCl, at 4 °C;  
453 (iii) in 100 µL of 15 mM sodium citrate pH 3.0 or 5.0, in 100 µL of 15 mM Tris-HCl  
454 pH 7.0 or 9.0, at 4 °C. In all cases after the 2 h of incubation time, the granules were

455 centrifuged at  $12,000 \times g$  for 15 min at 4 °C and the retained and soluble protein fractions  
456 were analyzed and estimated by SDS-PAGE as specified bellow. The percentage of  
457 discharged protein was obtained by subtracting the amount of protein liberated from the  
458 granules from the total amount of protein (sum of the soluble and insoluble fractions).  
459 Every assay was performed in duplicate.

#### 460 ***Protein Quantification***

461 The content of the different BioF and MinP-based-tag proteins on the granule surface was  
462 determined by imaging the bands separated on 12.5 % SDS-PAGE and estimating the  
463 amount of protein present using the software package *ImageJ*. Pellet and granule protein  
464 fractions of the crude extract and the granule fraction isolated from each culture were  
465 separated by SDS-PAGE and stained with Coomassie brilliant blue G-250 following the  
466 described protocol (44). The amount of protein anchored to the surface of the granules  
467 was estimated by imaging the Coomassie stained gels and taking into account the amount  
468 of isolated granules loaded in each well and calibrating against Precision Plus Protein  
469 Standards from BioRad®.

#### 470 ***PHA quantification***

471 Monomer composition and cellular content of PHA were determined by gas  
472 chromatography-mass spectrometry (GC-MS) following the previously described protocol  
473 (56). Briefly, PHA monomers were obtained by acid methanolysis with 2 mL of methanol  
474 acidified with 15 % H<sub>2</sub>SO<sub>4</sub> (v/v) and 2 mL of 0.5 mg/mL of 3-methyl benzoate in  
475 chloroform as an internal standard. This mixture was incubated for 5 h in an oil bath at  
476 100 °C. After cooling, 1 mL of distilled water was added to the mixture and centrifuged

477 for 10 min at 3,000 x g to separate the phases. A second step of extraction was  
478 performed to remove the residual H<sub>2</sub>SO<sub>4</sub>. Finally, a small amount of Na<sub>2</sub>SO<sub>4</sub> powder  
479 was added to remove residual water. The organic layer was analyzed using an Agilent  
480 7890A GC equipped with a DB-5HT capillary column (30 m length, 0.25 mm internal  
481 diameter, 0.1 μm film thickness), and mass data were acquired and processed with an  
482 Agilent 5975C mass spectrometer. The oven temperature program was set at an initial  
483 temperature of 80 °C for 2 min, then from 80 °C up to 115 °C at a rate of 5 °C/min for  
484 efficient separation of peaks. Spectra were obtained as electron impacts with an ionizing  
485 energy for MS operation of 70 eV.

486 Biomass calculation was carried out as previously described (56). Fifty millilitres of  
487 culture medium was centrifuged for 30 min at 3,000 x g at 4 °C and pellets were  
488 lyophilized for 24 h and weighed.

#### 489 ***Enzymatic activity assays***

490 Enzymatic activity was tested for the granule-immobilized fusion proteins after treatment  
491 at different pHs and temperature, and its relative activity was calculated regarding  
492 untreated granule-immobilized enzymes as follows:

#### 493 *β-galactosidase assay.*

494 Firstly, in order to determine specific activity (SA) of the immobilized enzyme, an aliquot  
495 of 12.5 μL of granules with a defined protein concentration (see *PHA granules isolation*  
496 *and Protein quantification sections*), was centrifuged (15 min, 16,060 x g, RT) and  
497 resuspended in 500 μL of 100 mM sodium phosphate pH 7.0 in 2 mL tubes, to which 500  
498 μL of Buffer Z (Na<sub>2</sub>HPO<sub>4</sub> 60 mM, NaH<sub>2</sub>PO<sub>4</sub> 40 mM, KCl 10 mM, MgSO<sub>4</sub> 1 mM, β-

499 mercaptoethanol 50 mM, pH 7.0) were added. The tubes were pre-warmed at 28 °C for 3  
500 min in a thermoblock (Fisher Scientific, USA) and subsequently, 200 µL of *O*-nitrophenyl-  
501 β-galactopyranoside (ONPG) (Sigma-Aldrich, USA) (4 mg·mL<sup>-1</sup>) were added and  
502 incubated for 3 min more, after which the reaction was stopped by the addition of 500 µL  
503 1 M Na<sub>2</sub>CO<sub>3</sub>, pH 11.0. Previously, we had determined both the protein concentration and  
504 the reaction time needed to measure the activity in the linear part of the activity curve. The  
505 ONP generated in the stopped reaction was measured at 420 nm in a spectrophotometer  
506 (DU®520, Beckman) and used for the SA calculation (units per mg of protein), by using  
507 an extinction coefficient of 4800 M<sup>-1</sup> cm<sup>-1</sup> for ONP. The SA of the immobilized MinP-β-  
508 galactosidase resulted to be 6,8 x 10<sup>4</sup> UA mg<sup>-1</sup>, in agreement with the SA reported for BioF-β-  
509 galactosidase (2,8 x 10<sup>5</sup> UA mg<sup>-1</sup>) (30). One unit of activity, UA, is defined as the amount  
510 of protein needed to hydrolyze 1 nmol of ONPG per min at 28 °C.

511 For the functional stability test, the granules containing the immobilized protein were  
512 previously treated as described in *stability of MinP-proteins attached to PHA granules*  
513 section (2 h at pH 3.0, 5.0, 7.0 or 9.0 and temperatures -20 °C, 4 °C, 37°C or 60 °C).  
514 Positive control was prepared with granules at pH 7.0 and at 4 °C for pH and temperature  
515 treatment respectively. As negative control, granules extracted from the parental strain *P.*  
516 *putida* KT2440 Δ*pha* + C1 incubated at 4 °C for 2 h were taken. The enzyme activity assay  
517 was undertaken as explained in the above paragraph except that, after stopping the reaction,  
518 and for the ONP quantification, an aliquot of 200 µL of each suspension was transferred  
519 to a multiwell plate (Falcon, USA) and the absorbance at 420 nm was measured in a  
520 VersaMax microplate reader (Molecular Devices). Enzyme activity was calculated as  
521 Miller Units by using the following formula: 1000 x (OD<sub>420</sub>) / (T x P) where T is the

522 reaction time in min; and P is the total amount of protein quantified by gel densitometry  
523 after the treatment (see *Protein quantification section*). The enzyme activity in each case  
524 was shown as percentage with regard to a control at pH 7.0 for the pH treatments, and at 4  
525 °C for the temperature treatments.

#### 526 *CueO assay*

527 In order to determine SA of the immobilized enzyme, an aliquot of 50 µL of granules (see  
528 *PHA granules isolation*) with a defined protein concentration as determined by gel  
529 densitometry, was centrifuged (15 min, 16,060 x g at room temperature) and resuspended  
530 in in the same volume of 100 mM sodium phosphate pH 6.5. The granules suspension was  
531 transferred to a spectrophotometer cuvette and the reaction was triggered by the addition  
532 of CuCl<sub>2</sub> (Fluka, Switzerland) and the CueO substrate 2,6 dimethoxyphenol (DMP)  
533 (Sigma-Aldrich, USA) at a final concentration of 10 µM and 2 mM respectively in 100  
534 mM sodium phosphate pH 6.5 and in a final volume of 1 ml. The reaction product,  
535 3,3',5,5'-tetramethoxydiphenoquinone, was followed at 30 °C by measuring the  
536 absorbance at 468 nm ( $\epsilon_{468\text{nm}} = 14\,800\text{ M}^{-1}\text{ cm}^{-1}$ ) (48) each 5 min in order to be sure to  
537 determine the activity in the linear part of the oxidation curve. The specific activity of the  
538 immobilized MinP-CueO resulted to be 2 300 UA mg<sup>-1</sup>, comparable with that of soluble  
539 CueO (6 000 UA mg<sup>-1</sup>), although slightly reduced probably due to the presence of the MinP  
540 fused moiety. One UA is defined as the amount of enzyme needed to oxidize 1 nmol of  
541 DMP per min and at 30 °C.

542 For the functional stability test, the granules containing the immobilized protein were  
543 previously treated as described in *stability of MinP-proteins attached to PHA granules*  
544 section (2 h at pH 3.0, 5.0, 7.0 or 9.0 and temperatures -20 °C, 4 °C, 37°C or 60 °C).

545 Positive control was prepared with granules at pH 7.0 and at 4 °C for pH and temperature  
546 treatment respectively. As negative control, granules with heat-inactivated MinP-CueO (2  
547 min, 98 °C) were used. For relative quantification, the assays were carried out in a  
548 multiwell plate (Falcon, USA) in a final volume of 200 µL and the activity monitored in a  
549 multiwell reader at OD<sub>468</sub> (VersaMax, Molecular devices).

## 550 **ACKNOWLEDGEMENTS**

551 This work was supported by the European Union's Horizon 2020 Research and Innovation  
552 Programme, grant agreement no. 633962 (P4SB), the Spanish Ministry of Science,  
553 Innovation and Universities (BIO2017-83448-R, BIO2016-79323-R, RTI2018-094564-  
554 B-I00) and the Community of Madrid (P2013/MIT2807, P2018/NMT4389). Francisco  
555 Blanco is a recipient of a predoctoral grant from the State Program for the Promotion of  
556 Talent and its Employability in R&D&I (PRE-2018-083859) from the Spanish Ministry of  
557 Science and Innovation.

558      **REFERENCES**

- 559    1.      Hay ID, Du J, Burr N, Rehm BHA. 2015. Bioengineering of bacteria to assemble custom-  
560      made polyester affinity resins. *Appl Environ Microbiol* 81:282-91.
- 561    2.      Li Z, Loh XJ. 2017. Recent advances of using polyhydroxyalkanoate-based nanovehicles  
562      as therapeutic delivery carriers. *WIREs Nanomed Nanobiotechnol* 9.
- 563    3.      Barbosa O, Ortiz C, Berenguer-Murcia A, Torres R, Rodrigues RC, Fernandez-Lafuente R.  
564      2015. Strategies for the one-step immobilization-purification of enzymes as industrial  
565      biocatalysts. *Biotechnol Adv* 33:435-56.
- 566    4.      Tortajada M, da Silva LF, Prieto MA. 2013. Second-generation functionalized medium-  
567      chain-length polyhydroxyalkanoates: the gateway to high-value bioplastic applications. *Int*  
568      *Microbiol* 16:1-15.
- 569    5.      Jendrossek D, Pfeiffer D. 2014. New insights in the formation of polyhydroxyalkanoate  
570      granules (carbonosomes) and novel functions of poly(3-hydroxybutyrate). *Environ*  
571      *Microbiol* 16:2357-73.
- 572    6.      Parlane NA, Gupta SK, Rubio-Reyes P, Chen S, Gonzalez-Miro M, Wedlock DN, Rehm  
573      BHA. 2017. Self-Assembled Protein-Coated Polyhydroxyalkanoate Beads: Properties and  
574      Biomedical Applications. *ACS Biomater Sci Eng* 3:3043-57.
- 575    7.      Dinjaski N, Prieto MA. 2015. Smart polyhydroxyalkanoate nanobeads by protein based  
576      functionalization. *Nanomedicine* 11:885-99.
- 577    8.      Maestro B, Sanz JM. 2017. Polyhydroxyalkanoate-associated phasins as phylogenetically  
578      heterogeneous, multipurpose proteins. *Microb Biotechnol* 10:1323-37.
- 579    9.      Mezzina MP, Pettinari MJ. 2016. Phasins, Multifaceted Polyhydroxyalkanoate Granule-

- 580 Associated Proteins. Appl Environ Microbiol 82:5060-7.
- 581 10. Li J, Shang G, You M, Peng S, Wang Z, Wu H, Chen GQ. 2011. Endotoxin removing  
582 method based on lipopolysaccharide binding protein and polyhydroxyalkanoate binding  
583 protein PhaP. Biomacromolecules 12:602-8.
- 584 11. Banki MR, Gerngross TU, Wood DW. 2005. Novel and economical purification of  
585 recombinant proteins: intein-mediated protein purification using *in vivo*  
586 polyhydroxybutyrate (PHB) matrix association. Protein Sci 14:1387-95.
- 587 12. Wang Z, Wu H, Chen J, Zhang J, Yao Y, Chen GQ. 2008. A novel self-cleaving phasin tag  
588 for purification of recombinant proteins based on hydrophobic polyhydroxyalkanoate  
589 nanoparticles. Lab Chip 8:1957-62.
- 590 13. Geng Y, Wang S, Qi Q. 2010. Expression of active recombinant human tissue-type  
591 plasminogen activator by using *in vivo* polyhydroxybutyrate granule display. Appl Environ  
592 Microbiol 76:7226-30.
- 593 14. Bello-Gil D, Maestro B, Fonseca J, Dinjaski N, Prieto MA, Sanz JM. 2018. Poly-3-  
594 Hydroxybutyrate Functionalization with BioF-Tagged Recombinant Proteins. Appl  
595 Environ Microbiol 84.
- 596 15. Bello-Gil D, Roig-Molina E, Fonseca J, Sarmiento-Ferrandez MD, Ferrandiz M, Franco E,  
597 Mira E, Maestro B, Sanz JM. 2018. An enzymatic system for decolorization of wastewater  
598 dyes using immobilized CueO laccase-like multicopper oxidase on poly-3-  
599 hydroxybutyrate. Microb Biotechnol 11:881-92.
- 600 16. Wong JX, Ogura K, Chen S, Rehm BHA. 2020. Bioengineered Polyhydroxyalkanoates as  
601 Immobilized Enzyme Scaffolds for Industrial Applications. Front Bioeng Biotechnol 8:156.
- 602 17. Moldes C, Farinos GP, de Eugenio LI, Garcia P, Garcia JL, Ortego F, Hernandez-Crespo

- 603 P, Castanera P, Prieto MA. 2006. New tool for spreading proteins to the environment:  
604 Cry1Ab toxin immobilized to bioplastics. *Appl Microbiol Biotechnol* 72:88-93.
- 605 18. Backstrom BT, Brockelbank JA, Rehm BH. 2007. Recombinant *Escherichia coli* produces  
606 tailor-made biopolyester granules for applications in fluorescence activated cell sorting:  
607 functional display of the mouse interleukin-2 and myelin oligodendrocyte glycoprotein.  
608 *BMC Biotechnol* 7:3.
- 609 19. Atwood JA, Rehm BH. 2009. Protein engineering towards biotechnological production of  
610 bifunctional polyester beads. *Biotechnol Lett* 31:131-7.
- 611 20. Yao YC, Zhan XY, Zhang J, Zou XH, Wang ZH, Xiong YC, Chen J, Chen GQ. 2008. A  
612 specific drug targeting system based on polyhydroxyalkanoate granule binding protein  
613 PhaP fused with targeted cell ligands. *Biomaterials* 29:4823-30.
- 614 21. Dong Y, Li P, Chen CB, Wang ZH, Ma P, Chen GQ. 2010. The improvement of fibroblast  
615 growth on hydrophobic biopolyesters by coating with polyhydroxyalkanoate granule  
616 binding protein PhaP fused with cell adhesion motif RGD. *Biomaterials* 31:8921-30.
- 617 22. You M, Peng G, Li J, Ma P, Wang Z, Shu W, Peng S, Chen GQ. 2011. Chondrogenic  
618 differentiation of human bone marrow mesenchymal stem cells on polyhydroxyalkanoate  
619 (PHA) scaffolds coated with PHA granule binding protein PhaP fused with RGD peptide.  
620 *Biomaterials* 32:2305-13.
- 621 23. Xie H, Li J, Li L, Dong Y, Chen GQ, Chen KC. 2013. Enhanced proliferation and  
622 differentiation of neural stem cells grown on PHA films coated with recombinant fusion  
623 proteins. *Acta Biomater* 9:7845-54.
- 624 24. Fan F, Wang L, Ouyang Z, Wen Y, Lu X. 2018. Development and optimization of a tumor  
625 targeting system based on microbial synthesized PHA biopolymers and PhaP mediated

- 626 functional modification. *Appl Microbiol Biotechnol* 102:3229-41.
- 627 25. Xue Q, Liu XB, Lao YH, Wu LP, Wang D, Zuo ZQ, Chen JY, Hou J, Bei YY, Wu XF,  
628 Leong KW, Xiang H, Han J. 2018. Anti-infective biomaterials with surface-decorated  
629 tachyplesin I. *Biomaterials* 178:351-362.
- 630 26. Prieto MA, Buhler B, Jung K, Witholt B, Kessler B. 1999. PhaF, a polyhydroxyalkanoate-  
631 granule-associated protein of *Pseudomonas oleovorans* GPo1 involved in the regulatory  
632 expression system for pha genes. *J Bacteriol* 181:858-68.
- 633 27. Galan B, Dinjaski N, Maestro B, de Eugenio LI, Escapa IF, Sanz JM, Garcia JL, Prieto MA.  
634 2011. Nucleoid-associated PhaF phasin drives intracellular location and segregation of  
635 polyhydroxyalkanoate granules in *Pseudomonas putida* KT2442. *Mol Microbiol* 79:402-  
636 18.
- 637 28. Maestro B, Galan B, Alfonso C, Rivas G, Prieto MA, Sanz JM. 2013. A new family of  
638 intrinsically disordered proteins: structural characterization of the major phasin PhaF from  
639 *Pseudomonas putida* KT2440. *PLoS One* 8:e56904.
- 640 29. Tarazona NA, Maestro B, Revelles O, Sanz JM, Prieto MA. 2019. Role of leucine zipper-  
641 like motifs in the oligomerization of *Pseudomonas putida* phasins. *Biochim Biophys Acta*  
642 *Gen Subj* 1863:362-70.
- 643 30. Moldes C, Garcia P, Garcia JL, Prieto MA. 2004. *In vivo* immobilization of fusion proteins  
644 on bioplastics by the novel tag BioF. *Appl Environ Microbiol* 70:3205-12.
- 645 31. Dinjaski N, Prieto MA. 2013. Swapping of phasin modules to optimize the *in vivo*  
646 immobilization of proteins to medium-chain-length polyhydroxyalkanoate granules in  
647 *Pseudomonas putida*. *Biomacromolecules* 14:3285-93.
- 648 32. Mato A, Tarazona NA, Hidalgo A, Cruz A, Jimenez M, Perez-Gil J, Prieto MA. 2019.


- 649 Interfacial Activity of Phasin PhaF from *Pseudomonas putida* KT2440 at Hydrophobic-  
650 Hydrophilic Bionterfaces. *Langmuir* 35:678-686.
- 651 33. Terpe K. 2003. Overview of tag protein fusions: from molecular and biochemical  
652 fundamentals to commercial systems. *Appl Microbiol Biotechnol* 60:523-33.
- 653 34. Gautier R, Douguet D, Antony B, Drin G. 2008. HELIQUEST: a web server to screen  
654 sequences with specific alpha-helical properties. *Bioinformatics* 24:2101-2.
- 655 35. Silva-Rocha R, Martinez-Garcia E, Calles B, Chavarria M, Arce-Rodriguez A, de Las Heras  
656 A, Paez-Espino AD, Durante-Rodriguez G, Kim J, Nickel PI, Platero R, de Lorenzo V. 2013.  
657 The Standard European Vector Architecture (SEVA): a coherent platform for the analysis  
658 and deployment of complex prokaryotic phenotypes. *Nucleic Acids Res* 41:D666-75.
- 659 36. Husain Q. 2010.  $\beta$  Galactosidases and their potential applications: a review. *Crit Rev*  
660 *Biotechnol* 30:41-62.
- 661 37. Patel N, Shahane S, Shivam, Majumdar R, Mishra U. 2019. Mode of Action, Properties,  
662 Production, and Application of Laccase: A Review. *Recent Pat Biotechnol* 13:19-32.
- 663 38. Mezzina MP, Wetzler DE, Catone MV, Bucci H, Di Paola M, Pettinari MJ. 2014. A phasin  
664 with many faces: structural insights on PhaP from *Azotobacter* sp. FA8. *PLoS One*  
665 9:e103012.
- 666 39. Zhao H, Wei H, Liu X, Yao Z, Xu M, Wei D, Wang J, Wang X, Chen GQ. 2016. Structural  
667 Insights on PHA Binding Protein PhaP from *Aeromonas hydrophila*. *Sci Rep* 6:39424.
- 668 40. Littlechild JA. 2015. Enzymes from Extreme Environments and Their Industrial  
669 Applications. *Front Bioeng Biotechnol* 3:161.
- 670 41. Sarmiento F, Peralta R, Blamey JM. 2015. Cold and Hot Extremozymes: Industrial  
671 Relevance and Current Trends. *Front Bioeng Biotechnol* 3:148.

- 672 42. Wieczorek R, Pries A, Steinbuchel A, Mayer F. 1995. Analysis of a 24-kilodalton protein  
673 associated with the polyhydroxyalkanoic acid granules in *Alcaligenes eutrophus*. *J*  
674 *Bacteriol* 177:2425-35.
- 675 43. Mezzina MP, Wetzler DE, de Almeida A, Dinjaski N, Prieto MA, Pettinari MJ. 2015. A  
676 phasin with extra talents: a polyhydroxyalkanoate granule-associated protein has chaperone  
677 activity. *Environ Microbiol* 17:1765-76.
- 678 44. Sambrook J. 2001. *Molecular cloning : a laboratory manual* / Joseph Sambrook, David W.  
679 Russell. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- 680 45. Bagdasarian M, Lurz R, Ruckert B, Franklin FC, Bagdasarian MM, Frey J, Timmis KN.  
681 1981. Specific-purpose plasmid cloning vectors. II. Broad host range, high copy number,  
682 RSF1010-derived vectors, and a host-vector system for gene cloning in *Pseudomonas*. *Gene*  
683 16:237-47.
- 684 46. Boyer HW, Roulland-Dussoix D. 1969. A complementation analysis of the restriction and  
685 modification of DNA in *Escherichia coli*. *J Mol Biol* 41:459-72.
- 686 47. Herrero M, de Lorenzo V, Timmis KN. 1990. Transposon vectors containing non-antibiotic  
687 resistance selection markers for cloning and stable chromosomal insertion of foreign genes  
688 in gram-negative bacteria. *J Bacteriol* 172:6557-67.
- 689 48. Grass G, Rensing C. 2001. CueO is a multi-copper oxidase that confers copper tolerance in  
690 *Escherichia coli*. *Biochem Biophys Res Commun* 286:902-8.
- 691 49. Zobel S, Benedetti I, Eisenbach L, de Lorenzo V, Wierckx N, Blank LM. 2015. Tn7-Based  
692 Device for Calibrated Heterologous Gene Expression in *Pseudomonas putida*. *ACS Synth*  
693 *Biol* 4:1341-51.
- 694 50. Pais J, Farinha I, Freitas F, Serafim LS, Martinez V, Martinez JC, Arevalo-Rodriguez M,

- 695 Auxiliadora Prieto M, Reis MA. 2014. Improvement on the yield of polyhydroxyalkanoates  
696 production from cheese whey by a recombinant *Escherichia coli* strain using the proton  
697 suicide methodology. *Enzyme Microb Technol* 55:151-8.
- 698 51. Kessler B, de Lorenzo V, Timmis KN. 1992. A general system to integrate lacZ fusions  
699 into the chromosomes of gram-negative eubacteria: regulation of the Pm promoter of the  
700 TOL plasmid studied with all controlling elements in monocopy. *Mol Gen Genet* 233:293-  
701 301.
- 702 52. Choi KH, Gaynor JB, White KG, Lopez C, Bosio CM, Karkhoff-Schweizer RR, Schweizer  
703 HP. 2005. A Tn7-based broad-range bacterial cloning and expression system. *Nat Methods*  
704 2:443-8.
- 705 53. Iverson SV, Haddock TL, Beal J, Densmore DM. 2016. CIDAR MoClo: Improved MoClo  
706 Assembly Standard and New *E. coli* Part Library Enable Rapid Combinatorial Design for  
707 Synthetic and Traditional Biology. *ACS Synth Biol* 5:99-103.
- 708 54. Fauchère JL, Pliska V. 1986. Reply from Fauchère and Pliska. *Trends in Biochemical*  
709 *Sciences* 11:70.
- 710 55. Eisenberg D, Weiss RM, Terwilliger TC. 1982. The helical hydrophobic moment: a  
711 measure of the amphiphilicity of a helix. *Nature* 299:371-4.
- 712 56. de Eugenio LI, Escapa IF, Morales V, Dinjaski N, Galan B, Garcia JL, Prieto MA. 2010.  
713 The turnover of medium-chain-length polyhydroxyalkanoates in *Pseudomonas putida*  
714 KT2442 and the fundamental role of PhaZ depolymerase for the metabolic balance. *Environ*  
715 *Microbiol* 12:207-21.

716

717 **Figures leyend**



718

719 **Fig 1. PHA production and granule structure.** A) TEM image of *P. putida* KT2440 growing

720 under PHA producing conditions. Granules are accumulated as hydrophobic inclusions inside

721 the cell. B) Schematic representation of the PHA granule from *P. putida* KT2440. The PHA


722 is surrounded by a layer of proteins called granule associated proteins (GAPs) such as PHA

723 polymerase, depolymerase and phasins.

724

725

726



727

728 **Fig 2. Evaluation of the structural aspects of the N-terminal domain of phasin PhaF(BioF)**

729 **and design of a set of BioF-based fragments.** A) Analysis of mean hydrophobicity( $\langle\langle H \rangle\rangle$ ) and

730 mean hydrophobic moment ( $\langle\langle \mu H \rangle\rangle$ ) of predicted  $\alpha$ -helical stretches within the PHA binding


731 and leucine zipper motifs of PhaF. Calculations were performed with the *HeliQuest* utilities

732 using a sequence window size of 18 aa (34). B) Schematic representation of the battery of BioF-

733 based peptides designed. BioF amino acid residue positions are indicated above, pink

734 corresponds to the N-terminal domain of PhaF, light pink corresponds to the conserved highly

735 hydrophobic motif (WLAGLGI), blue corresponds to the central leucine zipper motif.




737

738 **Fig 3.** Localization of the different Bi segment-GFP fusion proteins in *P. putida* KT2440 after  
 739 24 h of growth in 0.1 N M63 plus 15 mM of octanoate, induced at O.D.<sub>600</sub> 0.8 with 1 mM of  
 740 3-MB. BioF-G: *P. putida* KT2440 (pSP1BioF-G); Bi1-G: *P. putida* KT2440 (pSP1Bi1-G); Bi2-  
 741 G: *P. putida* KT2440 (pSP1Bi2-G); Bi3-G: *P. putida* KT2440 (pSP1Bi3-G); Bi4: *P. putida*  
 742 KT2440 (pSP1Bi4-G). A) *In vivo* localization of BioF-based tag segments fused to GFP by  
 743 epifluorescence and phase contrast microscopy. Scale bars mean 2 μm. B) SDS-PAGE stained  
 744 with Coomassie brilliant blue. The lanes contain the fractions isolated (SP: crude extract

745 supernatant, P: crude extract pellet, GR: isolated PHA granules). EV: *P. putida* KT2440  
 746 (pSP1) empty vector. The volume loaded in each well was 15  $\mu$ L. Red arrows indicate the  
 747 predicted molecular weights of the recombinant proteins.


748



749

750 **Fig 4.** Localization of the different Bi segment-GFP fusion proteins in *P. putida* KT2440  
 751  $\Delta$ pha+C1 after 24 h of growth in 0.1 N M63 plus 15 mM of octanoate, induced at O.D.<sub>600</sub> 0.8  
 752 with 1 mM of 3-MB. Bi1-G: *P. putida* KT2440  $\Delta$ pha+C1 (pSP1Bi1-G); Bi2-G: *P. putida*  
 753 KT2440  $\Delta$ pha+C1 (pSP1Bi2-G); BioF-G: *P. putida* KT2440  $\Delta$ pha+C1 (pSP1BioF-G); Bi3-G:  
 754 *P. putida* KT2440  $\Delta$ pha+C1 (pSP1Bi3-G). A) *In vivo* localization of BioF-based tag segments  
 755 fused to GFP by epifluorescence and phase contrast microscopy. Scale bars mean 2  $\mu$ m. B) SDS-  
 756 PAGE stained with Coomassie brilliant blue. The lanes contain the fractions isolated (SP:


757 crude extract supernatant, P: crude extract pellet, GR: isolated PHA granules). EV: *P. putida*  
758 KT2440  $\Delta pha+Cl$  (pSP1) empty vector. The volume loaded in each well was 15  $\mu$ L. Red arrows  
759 indicate the predicted molecular weights of the recombinant proteins.  
760



761  
762 **Fig 5.** Percentage of protein released from isolated PHA granules of *P. putida* KT2440  
763  $\Delta pha+Cl$  (pSP1Bi1-G), *P. putida* KT2440  $\Delta pha+Cl$  (pSP1BioF-G) and *P. putida* KT2440  
764  $\Delta pha+Cl$  (pSP1Bi3-G) after treatment for 2 h with various concentrations of Triton X-100 at  
765 room temperature and separating released (supernatant) and PHA-bound protein (pellet).  
766 Percentages refer to the ratio between soluble fraction to the total amount of protein (sum of  
767 soluble and insoluble fractions) using *ImageJ* to quantitate band intensities on Coomassie-


768 stained SDS-PAGE. Error bars represent the SD from three biological replicates and two  
769 technical each.

770



771

772 **Fig 6.** Coomassie stained SDS-PAGE of PHA granules extracted from *P. putida* KT2440  
773  $\Delta pha+C1$  producing Bi1-G. The stability of Bi1-G interacting with PHA granules was  
774 assessed by exposure a range of temperatures (A), pH (B) and ionic strength (C) for 2 h. A)  
775 Lanes 1-4, released soluble fraction after at -20 °C, 4 °C, 37 °C and 60 °C, respectively. Lanes  
776 5-8, PHA granule retained protein fraction after treatment at -20 °C, 4 °C, 37 °C and 60 °C,  
777 respectively; Lane 9, untreated isolated granules. B) Lanes 1-4, released soluble fraction after  
778 treatment with pH 3.0, 5.0, 7.0 and 9.0, respectively. Lanes 5-8, PHA granule retained protein  
779 fraction after treatment at pH 3.0, 5.0, 7.0 and 9.0, respectively. C) Lanes 1-4, released soluble  
780 fraction after treatment with 0,10, 100 and 1000 mM NaCl, respectively. Lanes 5-8, PHA granule  
781 retained protein fraction after treatment with 0, 10, 100 and 1000 mM NaCl, respectively.  
782 Volumes loaded correspond to 15  $\mu$ L of the soluble and insoluble fractions obtained after the  
783 treatment of the granules.




785

786 **Fig 7.** A) pSMinPN plasmid derived from pSEVA238 to generate MinP N-terminal fusion  
787 proteins for the production of customized protein functionalized PHA nanobeads. B) *In vivo*  
788 localization of the MinP-GFP produced by *P. putida* KT2440  $\Delta$ pha+Cl (pSMinP-1) after 24 h

789 of growth in PHA producing conditions. Scale bars mean 2  $\mu\text{m}$ . C) Nucleotide sequence of the  
790 *minP-Linker-MCS* construction. *minP* gene is represented in pink, Linker region in light  
791 green and restriction sites are underlined with different colours (*NdeI*, *XhoI*, *KpnI*, *BamHI*, *PstI*,  
792 *XhoI*, *HindIII*).

793



794

795 **Fig 8.** Percentage of activity retained by the protein immobilized at the granule after treatment  
796 at different pHs, with respect to a control at pH 7.0 (left panels), or temperatures, with respect  
797 to a control at 4 °C (right panels), for both MinP- $\beta$ -galactosidase (A, B) and MinP-CueO (C, D).  
798 Error bars represent SD from 3–5 biological replicates.

799



800

801 **Fig 9. *Pha* minimal cluster for the construction of *P. putida* KT2440  $\Delta$ *pha*+C1. 14a:**

802 Promoter (49); T0: Lambda T0 terminator. *phaC1*: PhaC1 synthase coding gene from *P.*

803 *putida* KT2440. *P*, *S*, *1* and *2*: overlap regions for Gibson Assembly technique (53).

804

805 **Table 1.** Quantification of PHA production by GC-MS and determination of PHA granule  
 806 associated protein.

<b>Strain</b>	<b>CDW (g/L)</b>	<b>PHA (% of CDW)</b>	<b>Protein on granule surface (mg/g PHA)</b>	<b>Protein on granule surface (<math>\mu</math>M/g PHA)</b>
KT2440 (WT)	1.47 $\pm$ 0.04	70 $\pm$ 4	-	-
KT2440 pSP1	0.79 $\pm$ 0.00	51 $\pm$ 2	-	-
KT2440 pSP1BioF-G	0.90 $\pm$ 0.03	54.7 $\pm$ 0.6	6 $\pm$ 1	0.14 $\pm$ 0.03
KT2440 pSP1Bi1-G	0.98 $\pm$ 0.05	54.7 $\pm$ 2.4	7.4 $\pm$ 1.3	0.2 $\pm$ 0.04
KT2440 pSP1Bi2-G	0.82 $\pm$ 0.01	55 $\pm$ 2		
$\Delta$ pha+C1	0.73 $\pm$ 0.04	23 $\pm$ 2	-	-
$\Delta$ pha+C1 pSP1	0.63 $\pm$ 0.00	28 $\pm$ 4	-	-
$\Delta$ pha+C1 pSP1BioF-G	0.74 $\pm$ 0.05	38 $\pm$ 3	8.0 $\pm$ 0.7	0.17 $\pm$ 0.01
$\Delta$ pha+C1 pSP1Bi1-G	0.65 $\pm$ 0.01	27 $\pm$ 4	5.8 $\pm$ 0.9	0.16 $\pm$ 0.02
$\Delta$ pha+C1 pSP1Bi2-G	0.59 $\pm$ 0.01	27 $\pm$ 3	-	-

807

808

809

**Table 2.** Percentage of granule-attached protein after 2 h of the corresponding treatment.

		<b>MinP-CueO</b>	<b>MinP-<math>\beta</math>-galactosidase</b>
		<b>Mean (%)</b>	<b>Mean (%)</b>
pH	3	97 ( $\pm$ 2)	94 ( $\pm$ 10)
	5	96 ( $\pm$ 3)	94 ( $\pm$ 10)
	7	94 ( $\pm$ 5)	97 ( $\pm$ 1)
	9	83 ( $\pm$ 13)	89 ( $\pm$ 8)
[NaCl] mM	0	86 ( $\pm$ 8)	89 ( $\pm$ 3)
	10	96 ( $\pm$ 2)	91 ( $\pm$ 2)
	100	87 ( $\pm$ 8)	98 ( $\pm$ 1)
	1000	91 ( $\pm$ 8)	96 ( $\pm$ 6)
Temperature ( $^{\circ}$ C)	- 20	92 ( $\pm$ 7)	85 ( $\pm$ 9)
	4	96 ( $\pm$ 4)	84 ( $\pm$ 9)
	37	91 ( $\pm$ 5)	76 ( $\pm$ 3)
	60	91 ( $\pm$ 5)	ND

810

811

812 **Table3.** Strains, plasmids and oligonucleotides used in this work.

<b>Strains</b>	<b>Description</b>	<b>Reference</b>
<i>Pseudomonas</i>		
<i>putida</i>		
KT2440	Wild-type strain derived of <i>P. putida</i> mt-2 cured of the pWW0 plasmid	(45)
KT2440 $\Delta$ <i>pha</i>	Strain with the <i>pha</i> cluster deleted	CECT 30020
KT2440 $\Delta$ <i>pha</i> + <i>C1</i>	Strain with <i>phaC1</i> genes integrated into the genome of KT2440 $\Delta$ <i>pha</i> under the control of $P_{14a}$ promoter	This work
<i>Escherichia coli</i>		
DH10B	Host for <i>E. coli</i> plasmids	Invitrogen, Thermo Fisher Scientific, USA
HB101	Host for plasmid pRK600	(46)
CC118 $\lambda$ pir	Host strain for plasmid pTnS-1	(47)
DH5 $\alpha$ pir	Km <sup>R</sup> , XylS/ <i>Pm</i> , pBBR1 ori	Prieto lab collection

## Plasmids

pSEVA238	Km <sup>R</sup> , XylS/ <i>P<sub>m</sub></i> , pBBR1 ori	(35)
pSEVA225	Km <sup>R</sup> , LacZ, RK2 ori (source of $\beta$ -galactosidase)	(35)
pCueO	pASK-IBA3 derivative containing the <i>cueO</i> sequence. Cm <sup>R</sup> , f1 ori	(48)
pSP1	pSEVA238 derivate containing an RBS cloned into <i>Xba</i> I and <i>Hind</i> III sites	This work
pSP1Bi1-G	pSP1 derivate harboring the fusion gene <i>bi1-gfp</i>	This work
pSP1Bi2-G	pSP1 derivate harboring the fusion gene <i>bi2-gfp</i>	This work
pSP1Bi3-G	pSP1 derivate harboring the fusion gene <i>bi3-gfp</i>	This work
pSP1BioF-G	pSP1 derivative harboring the fusion gene <i>bioF-gfp</i>	This work
pSP1Bi4-G	pSP1 derivate harboring the fusion gene <i>bi4-gfp</i>	This work

pSMinPN	pSP1 derivate containing the <i>minP</i> sequence followed by a glycine rich region and a MCS	This work
pSMinP-1	pSMinPN derivative containing the GFP sequence cloned into <i>XhoI</i> and <i>HindIII</i> sites	This work
pSMinP-2	pSMinPN derivative containing the <i>lacZ</i> sequence cloned into <i>XhoI</i> and <i>BamHI</i> sites	This work
pSMinP-3	pSMinPN derivative containing the <i>cueO</i> sequence cloned into <i>XhoI</i> and <i>HindIII</i> sites	This work
pTn7	Km <sup>R</sup> Gm <sup>R</sup> , ori R6K, Tn7L and Tn7R extremes, standard multiple cloning site	(49)
pTn7-ModC1	pTn7 derivate harboring <i>phaC1</i> gene	This work
pMAB20-GFP-LYTAG	pMAB20 derivate harboring the fusion gene <i>bioF-gfp-lytag</i>	(50)
pRK600	Cm <sup>R</sup> , ori <i>ColE1</i> , <i>tra+mob+</i> of <i>RK2</i>	(51)
pTnS-1	Ap <sup>R</sup> , ori R6K, <i>TnSABC+D</i> operon	(52)

## Oligonucleotide

**primers**

GFP-F            GGAAGTCCCATATGGAACCGCTCGAGATGATCATGGGAATTCAT  
AA

GFP-R            CATGCAAAGCTTTATTTGTAGAGTTCATCCATGCCG

Bio1-F            GGAAGTCCCATATGGCTGGCAAGAAGAACAC

Bio1-R            ATGCACTCGAGCTTCACCAGCGAGTCGAACA

Bio3-F            GGAAGTCCCATATGCTTAACAGCGCCATCTCG

Bio3-R            ATGCACTCGAGGGCGCGACGAAATCGGCGTAA

Bio4R            ATGCACTCGAGAGTGGTCGAAGACTTGGCAGT

MinPNt-F        GGAAGTCTGAATTCAATAATTTTGTTTAACTTTAAGAAGGAGA  
TATACATATGGCTGGCAAGAAGAAC

MinPNt-R        ATATCAAAGCTTCTGCAGGTCGACTCT

BamHI-GFP-F    GGAAGTCTGGATCCATGCGTAAAGGAGAAGAACT

XhoI-GFP-R      ATATCCTCGAGTGGTACCGGCCACCCCCT

XhoI-CueO-F     AGTCTTCTCGAGGCAGAACGCCCAACGTTACCGAT

HindIII-CueO-R  TCAGAATTCGAAAAATATGGCATTGTTGGGATTG

XhoI-LacZ-F      TCTGGCTCGAGATGACCATGATTACGGATTCACTG

BamHI-LacZ-R    AGTCTTGGATCCATTATTTTTGACACCAGACCAACTG

813